-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Medical Network, June 8 News On June 4, the application for the generic listing of Tedizolamide Phosphate for Injection declared by Nanjing Chia Tai Tianqing was accepted by CDE.
At present, the injection only has import approval, and no domestic imitation has been approved for the time being
.
Since the beginning of this year, Nanjing Chia Tai Tianqing has filed a clinical application for a Class 1 new drug and two applications for the marketing of high-end generic drugs
.
At present, the injection only has import approval, and no domestic imitation has been approved for the time being
.
Since the beginning of this year, Nanjing Chia Tai Tianqing has filed a clinical application for a Class 1 new drug and two applications for the marketing of high-end generic drugs
.
Figure 1: The status of new drugs and generic products declared by Nanjing Chia Tai Tianqing since 2021
Source: CDE official website
In March 2019, Bayer's tedizolamide phosphate tablets and injections were approved for marketing by NMPA, and the approved indications are acute skin and skin tissue infections in adults caused by gram-positive bacteria
.
Compared with the first-generation oxazolidinone antibiotic, linezolid, Tedizolid has two main advantages: one is that it is used once a day for six days, which is more convenient than linezolid twice a day for ten days; There are injections and tablets in the dosage form, which is convenient for clinical switching, reduces the patient's hospitalization time, and thus reduces the cost
.
.
Compared with the first-generation oxazolidinone antibiotic, linezolid, Tedizolid has two main advantages: one is that it is used once a day for six days, which is more convenient than linezolid twice a day for ten days; There are injections and tablets in the dosage form, which is convenient for clinical switching, reduces the patient's hospitalization time, and thus reduces the cost
.
Figure 2: The situation of Tedizolamide Phosphate for Injection that has been declared for imitation and marketing
Source: One-click search on Mi Nei.
com
com
From the date the contractor point of view, the Yangtze River was first declared in 2019 four types of imitation, in January 2021 to become the second declaration Sunrise pharmaceutical companies , now NJCTT into the fray, first imitation of war more competitive
.
.
NTQ1062 tablet is the first class 1 new drug declared by Nanjing Chia Tai Tianqing in 2021, which belongs to oncology drugs.
At present, clinical applications with two acceptance numbers have been accepted
.
At present, clinical applications with two acceptance numbers have been accepted
.
In addition to import approvals for lanthanum carbonate chewable tablets currently on the domestic market, Hunan Mingrui Pharmaceuticals will be approved for 6 types of imitation in 2020.
At present, Nanjing Zhengda Tianqing, Sichuan Pride Times Pharmaceuticals, and Shenyang Funing Pharmaceuticals are applying for 4 types of imitation listings.
In the review and approval, who can win the first review in China is worth looking forward to
.
At present, Nanjing Zhengda Tianqing, Sichuan Pride Times Pharmaceuticals, and Shenyang Funing Pharmaceuticals are applying for 4 types of imitation listings.
In the review and approval, who can win the first review in China is worth looking forward to
.
Table 1: Products approved by Nanjing Chia Tai Tianqing since 2020
Source: Meinenet MED2.
0 Chinese Drug Evaluation Database
0 Chinese Drug Evaluation Database
According to data from Minai.
com, in 2020, Nanjing Chia Tai Tianqing has 8 generic drugs successfully approved for listing, and 7 of them are deemed to have been reviewed according to the new classification.
Since 2021, Nanjing Chia Tai Tianqing has won 4 tolvaptan tablets.
Similar imitations were approved and deemed to have been reviewed, becoming the second domestic company approved for this product
.
com, in 2020, Nanjing Chia Tai Tianqing has 8 generic drugs successfully approved for listing, and 7 of them are deemed to have been reviewed according to the new classification.
Since 2021, Nanjing Chia Tai Tianqing has won 4 tolvaptan tablets.
Similar imitations were approved and deemed to have been reviewed, becoming the second domestic company approved for this product
.
Source: CDE official website, Minet.
com database
com database
The review data statistics are as of June 7.
If there are any errors or omissions, please correct me
.
If there are any errors or omissions, please correct me
.
Medical Network, June 8 News On June 4, the application for the generic listing of Tedizolamide Phosphate for Injection declared by Nanjing Chia Tai Tianqing was accepted by CDE.
At present, the injection only has import approval, and no domestic imitation has been approved for the time being
.
Since the beginning of this year, Nanjing Chia Tai Tianqing has filed a clinical application for a Class 1 new drug and two applications for the marketing of high-end generic drugs
.
At present, the injection only has import approval, and no domestic imitation has been approved for the time being
.
Since the beginning of this year, Nanjing Chia Tai Tianqing has filed a clinical application for a Class 1 new drug and two applications for the marketing of high-end generic drugs
.
Figure 1: The status of new drugs and generic products declared by Nanjing Chia Tai Tianqing since 2021
Source: CDE official website
In March 2019, Bayer's tedizolamide phosphate tablets and injections were approved for marketing by NMPA, and the approved indications are acute skin and skin tissue infections in adults caused by gram-positive bacteria
.
Compared with the first-generation oxazolidinone antibiotic, linezolid, Tedizolid has two main advantages: one is that it is used once a day for six days, which is more convenient than linezolid twice a day for ten days; There are injections and tablets in the dosage form, which is convenient for clinical switching, reduces the patient's hospitalization time, and thus reduces the cost
.
.
Compared with the first-generation oxazolidinone antibiotic, linezolid, Tedizolid has two main advantages: one is that it is used once a day for six days, which is more convenient than linezolid twice a day for ten days; There are injections and tablets in the dosage form, which is convenient for clinical switching, reduces the patient's hospitalization time, and thus reduces the cost
.
Figure 2: The situation of Tedizolamide Phosphate for Injection that has been declared for imitation and marketing
Source: One-click search on Mi Nei.
com
com
From the date the contractor point of view, the Yangtze River was first declared in 2019 four types of imitation, in January 2021 to become the second declaration Sunrise pharmaceutical companies , now NJCTT into the fray, first imitation of war more competitive
.
.
NTQ1062 tablet is the first class 1 new drug declared by Nanjing Chia Tai Tianqing in 2021, which belongs to oncology drugs.
At present, clinical applications with two acceptance numbers have been accepted
.
At present, clinical applications with two acceptance numbers have been accepted
.
In addition to import approvals for lanthanum carbonate chewable tablets currently on the domestic market, Hunan Mingrui Pharmaceuticals will be approved for 6 types of imitation in 2020.
At present, Nanjing Zhengda Tianqing, Sichuan Pride Times Pharmaceuticals, and Shenyang Funing Pharmaceuticals are applying for 4 types of imitation listings.
In the review and approval, who can win the first review in China is worth looking forward to
.
At present, Nanjing Zhengda Tianqing, Sichuan Pride Times Pharmaceuticals, and Shenyang Funing Pharmaceuticals are applying for 4 types of imitation listings.
In the review and approval, who can win the first review in China is worth looking forward to
.
Table 1: Products approved by Nanjing Chia Tai Tianqing since 2020
Source: Meinenet MED2.
0 Chinese Drug Evaluation Database
0 Chinese Drug Evaluation Database
According to data from Minai.
com, in 2020, Nanjing Chia Tai Tianqing has 8 generic drugs successfully approved for listing, and 7 of them are deemed to have been reviewed according to the new classification.
Since 2021, Nanjing Chia Tai Tianqing has won 4 tolvaptan tablets.
Similar imitations were approved and deemed to have been reviewed, becoming the second domestic company approved for this product
.
com, in 2020, Nanjing Chia Tai Tianqing has 8 generic drugs successfully approved for listing, and 7 of them are deemed to have been reviewed according to the new classification.
Since 2021, Nanjing Chia Tai Tianqing has won 4 tolvaptan tablets.
Similar imitations were approved and deemed to have been reviewed, becoming the second domestic company approved for this product
.
Source: CDE official website, Minet.
com database
com database
The review data statistics are as of June 7.
If there are any errors or omissions, please correct me
.
If there are any errors or omissions, please correct me
.
Medical Network, June 8 News On June 4, the application for the generic listing of Tedizolamide Phosphate for Injection declared by Nanjing Chia Tai Tianqing was accepted by CDE.
At present, the injection only has import approval, and no domestic imitation has been approved for the time being
.
Since the beginning of this year, Nanjing Chia Tai Tianqing has filed a clinical application for a Class 1 new drug and two applications for the marketing of high-end generic drugs
.
At present, the injection only has import approval, and no domestic imitation has been approved for the time being
.
Since the beginning of this year, Nanjing Chia Tai Tianqing has filed a clinical application for a Class 1 new drug and two applications for the marketing of high-end generic drugs
.
Figure 1: The status of new drugs and generic products declared by Nanjing Chia Tai Tianqing since 2021
Source: CDE official website
In March 2019, Bayer's tedizolamide phosphate tablets and injections were approved for marketing by NMPA, and the approved indications are acute skin and skin tissue infections in adults caused by gram-positive bacteria
.
Compared with the first-generation oxazolidinone antibiotic, linezolid, Tedizolid has two main advantages: one is that it is used once a day for six days, which is more convenient than linezolid twice a day for ten days; There are injections and tablets in the dosage form, which is convenient for clinical switching, reduces the patient's hospitalization time, and thus reduces the cost
.
.
Compared with the first-generation oxazolidinone antibiotic, linezolid, Tedizolid has two main advantages: one is that it is used once a day for six days, which is more convenient than linezolid twice a day for ten days; There are injections and tablets in the dosage form, which is convenient for clinical switching, reduces the patient's hospitalization time, and thus reduces the cost
.
Figure 2: The situation of Tedizolamide Phosphate for Injection that has been declared for imitation and marketing
Source: One-click search on Mi Nei.
com
com
From the date the contractor point of view, the Yangtze River was first declared in 2019 four types of imitation, in January 2021 to become the second declaration Sunrise pharmaceutical companies , now NJCTT into the fray, first imitation of war more competitive
.
Enterprise business enterprise.
NTQ1062 tablet is the first class 1 new drug declared by Nanjing Chia Tai Tianqing in 2021, which belongs to oncology drugs.
At present, clinical applications with two acceptance numbers have been accepted
.
Tumor tumor tumorAt present, clinical applications with two acceptance numbers have been accepted
.
In addition to import approvals for lanthanum carbonate chewable tablets currently on the domestic market, Hunan Mingrui Pharmaceuticals will be approved for 6 types of imitation in 2020.
At present, Nanjing Zhengda Tianqing, Sichuan Pride Times Pharmaceuticals, and Shenyang Funing Pharmaceuticals are applying for 4 types of imitation listings.
In the review and approval, who can win the first review in China is worth looking forward to
.
At present, Nanjing Zhengda Tianqing, Sichuan Pride Times Pharmaceuticals, and Shenyang Funing Pharmaceuticals are applying for 4 types of imitation listings.
In the review and approval, who can win the first review in China is worth looking forward to
.
Table 1: Products approved by Nanjing Chia Tai Tianqing since 2020
Source: Meinenet MED2.
0 Chinese Drug Evaluation Database
0 Chinese Drug Evaluation Database
According to data from Minai.
com, in 2020, Nanjing Chia Tai Tianqing has 8 generic drugs successfully approved for listing, and 7 of them are deemed to have been reviewed according to the new classification.
Since 2021, Nanjing Chia Tai Tianqing has won 4 tolvaptan tablets.
Similar imitations were approved and deemed to have been reviewed, becoming the second domestic company approved for this product
.
com, in 2020, Nanjing Chia Tai Tianqing has 8 generic drugs successfully approved for listing, and 7 of them are deemed to have been reviewed according to the new classification.
Since 2021, Nanjing Chia Tai Tianqing has won 4 tolvaptan tablets.
Similar imitations were approved and deemed to have been reviewed, becoming the second domestic company approved for this product
.
Source: CDE official website, Minet.
com database
com database
The review data statistics are as of June 7.
If there are any errors or omissions, please correct me
.
If there are any errors or omissions, please correct me
.
